EGFR and breast carcinoma: These compounds were tested in appropriate cellular models, which included the NSCLC cells with mutated EGFR, HCC827, the NSCLC cells carrying the EML4-ALK translocation, H3122, the breast cancer cells with amplified HER2, BT474 and SKBR3, and the regorafenib-sensitive colorectal cancer cells HCT116, by measuring viability with the MTS-based assay CellTiter96 Aqueous 1.